Emplicure enters evaluation agreement with a global healthcare company
Emplicure has signed a collaboration agreement with a global company for product evaluations. The aim with the project is to evaluate the use of Emplicure's platforms based on ceramic materials for oral delivery of the company's probiotic bacteria.
Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in April 2022 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to to give preference for more shareholders.
Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.
Anna-Lena Nicolson, CFO och medlem i ledningsgruppen i Emplicure AB (publ), har idag beslutat att lämna sitt uppdrag. Anna-Lena kommer att kvarstå som CFO till och med den 31 december 2021. Processen med att rekrytera hennes ersättare har inletts.
Som tidigare kommunicerats har Emplicure AB (publ) ("Emplicure" eller "Bolaget") genomfört en unitemission av aktier och teckningsoptioner av serie TO1 ("Teckningsoptionerna") i samband med en börsnotering på Nasdaq First North Growth Market. Första dag för handel med Teckningsoptionerna på Nasdaq First North Growth Market är den 19 juli 2021.